VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISA 2022 | RNAi therapy in patients with hATTR amyloidosis with cardiac and neurologic involvement

Marcus Anthony Urey, MD, University of California, San Diego, CA, comments on the use of RNA interference (RNAi) therapy in patients with hereditary transthyretin-mediated (hATTR) amyloidosis who have both cardiac and neurological involvement. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Disclosures

Consultancy: Alnylam, Akcea, BridgeBio
Honoraria: Pfizer
Research support: Ionis

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter